Carfilzomib consolidation with cyclophosphamide and dexamethasone conferred noninferior results compared to upfront autologous stem cell transplantation in newly diagnosed, transplant-eligible patients with multiple myeloma.
Recent Content
- Darzalex Faspro is first FDA-approved therapy for high-risk smoldering multiple myeloma
- Darzalex Faspro is first FDA-approved therapy for high-risk smoldering multiple myeloma
- FDA speeds development of oral pancreatic cancer treatment
- (no title)
- (no title)
- Oral safusidenib begins trial as maintenance for high-grade glioma
- Outcomes of relapse after teclistamab therapy in multiple myeloma
- Canada agency backs coverage of new ovarian cancer drug
- (no title)
- Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma